Circulating tumour DNA (ctDNA) in patients with colorectal cancer and the relationship to imaging features of extramural venous invasion
IRAS Number: 136894
CPMS ID: 19730
ClinicalTrials.gov ID: NCT02579278
Trial Start Date: Oct-15
Recruitment End Date: Dec-26
Trial End date: Nov-29
Extramural venous invasion (EMVI) is the spread of microscopic tumour cells into the veins around the tumour. When people develop cancer, microscopic cells and fragments of DNA can be released into the blood circulation. This could be one way that cancers recur in the future. We hope to identify differences within the blood in certain types of rectal cancer which will help us improve future treatments.
A multicentre observational study, ctDNA aims to provide the evidence base for metatstatic disease being caused by vascular methods of spread by determining if there is a link between EMVI status and ctDNA.
This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery. A pre operative staging scan must have been completed within 6 weeks prior to surgery. Two x 20ml blood samples will be taken from each patient, one prior to and one during or within 24hrs after surgery. Patients are annually followed up to 3 years.
The ctDNA trial is open to new sites.
Please fill in the form below if you would like further information or have any questions about any aspect of the trial.
